From our very first day as a company to today, our exceptional team has sought to propel the very best scientific ideas beyond the bench all the way to the bedside, ensuring that life-changing therapies reach their full potential and get to patients in need.

We achieved this goal with APHEXDA® (motixafortide), the next-generation, best-in-class stem cell mobilization agent that we successfully shepherded from early clinical development through FDA approval and commercial launch in September 2023.

With the successful commercial out-licensing of APHEXDA® completed, BioLineRx has returned to its roots as a lean development company, but with much broader and deeper knowledge of what it takes to successfully develop a therapeutic agent – what I like to call “BioLineRx 2.0”. Our mission as BioLineRx 2.0 is unchanged, namely, to identify and develop best-in-class treatments for cancer and rare diseases.

Together with our partners, we continue to advance in pancreatic ductal adenocarcinoma (PDAC). If successful, our PDAC program, which operates at minimal cost to the company, has the potential to meaningfully address the significant unmet need for this devastating disease.

Looking ahead, we are focused on in-licensing additional assets. The company’s long-term vision is to develop important therapies with significant potential value – with development costs offset from existing commercial partnerships. In this regard, BioLine is well-positioned to leverage its many years of relevant experience, unmatched drive and focus, and united entrepreneurial spirit to attract strong partners and eventually drive new, high-impact drugs through clinical development.

Philip Serlin

Chief Executive Officer